Drug Trial Radar · NCT07787091
A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Aug 19, 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Arditus Pte LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 21 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is evaluating ARD001, an investigational medicine being developed for the treatment of hemophilia A. In Phase 1, healthy adult participants will receive a single dose of ARD001 or placebo to assess its safety and tolerability, how it moves through the body, its effects on blood coagulation, and whether the body develops antibodies against it. If the Phase 1 results support further study and the required regulatory and ethics approvals are obtained, Phase 2 will evaluate repeated doses of ARD001 in adults with hemophilia A. Phase 2 is not currently open for enrollment. The study is designed to determine whether ARD001 can be administered with acceptable safety and to identify doses suitable for further clinical development.
Conditions
- Hemophilia A
- Healthy Adult Participants
Interventions
ARD001Biological
ARD001 will be administered subcutaneously as a single dose of 0.01, 0.1, or 0.3 mg/kg in Phase 1. A multiple-dose regimen is planned for Phase 2 and will be specified in a protocol amendment before Phase 2 initiation
PlaceboOther
The corresponding placebo will be administered subcutaneously as a single dose in Phase 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Treatment-Emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special InterestTime frame: From first dose through Day 29 for Cohort A1 and Day 113 for Cohorts A2 and A3.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SingHealth Investigational Medicine Unit
Singapore, Singapore · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.